At the highest dose tested, a single intravenous infusion of the CRISPR therapy CTX310 lowered LDL cholesterol by 52.5% from baseline at 12 months, and triglycerides by 47.8%. The result comes from a phase 1 study of 15 patients, who were followed for a year after treatment, and it is the first durability report for a treatment that edits the liver once and leaves the change in place.
Luke Laffin, M.D., a Cleveland Clinic cardiologist and lead author, reported the one-year data in the New England Journal of Medicine with a team that includes Steven Nissen, Stephen Nicholls and colleagues from the trial sites. Funding came from CRISPR Therapeutics AG of Zug, Switzerland, which developed the therapy, a detail that belongs beside the efficacy numbers.
An edit to ANGPTL3, delivered in one dose
CTX310 is a CRISPR-Cas9 editor packaged in a lipid nanoparticle and infused into a vein, from where it is taken up by liver cells. Its target is ANGPTL3, a gene whose protein restrains the enzymes that clear fats from the blood. Cleveland Clinic’s release describes the 15-patient trial as switching that gene off in the liver, which is why one infusion can in principle produce a lasting change instead of the daily or monthly dosing that statins and injectable antibodies require.
Doses ranged from 0.1 to 0.8 mg/kg, and patients received corticosteroids and antihistamines beforehand to blunt infusion reactions. According to CRISPR Therapeutics’ report of the data, the 15 participants were enrolled across four sequential dose cohorts, and eligibility required triglycerides above 150 mg/dL, LDL above 100 mg/dL, or both, despite standard-of-care therapy.
Reading the 52.5% at the top dose
The 52.5% LDL reduction applies to the top dose, not to all 15 patients. The published summaries give the 0.8 mg/kg cohort’s result but not how many of the 15 patients received that dose, and the lower-dose cohorts, by design, did less. The company’s release puts the highest-dose mean LDL reduction at 53% with a best individual response of 84%, a mean ANGPTL3 reduction of 79% with a maximum of 89%, and a mean triglyceride reduction of 48% with a maximum of 78%.
Those averages hide a spread. A best-responder figure of 84% next to a mean of 53% means some patients at the top dose cleared far less than half of their LDL, while others cleared most of it, and a 15-person study cannot say what predicts the difference.
Durability is the point of the follow-up. A single-dose gene editor is only worth developing if the effect lasts, since the entire argument for it is that a patient who struggles with daily pills or periodic injections could be treated once. Adherence is the gap CRISPR Therapeutics’ principal investigator names in the company release, saying a single infusion producing durable reductions at one year is an encouraging signal that a one-time approach could help close it. Cleveland Clinic’s Consult QD summary of the correspondence in NEJM reports ANGPTL3 down 78.6%, LDL down 52.5%, triglycerides down 47.8% and apolipoprotein B down 37.2% at one year at 0.8 mg/kg. Nissen is quoted there saying the good news is that ANGPTL3 and lipid levels “remained low and flat through the full year,” which he reads as a sign that the gene is being edited very efficiently. Flat curves are what a permanent edit should produce; a drug washing out would slope upward.
Safety, funding and the limits of 15 patients
No serious adverse events related to the therapy were reported during the one-year follow-up. Laffin said in the release, according to ScienceDaily’s repost, “It is encouraging that there were no serious safety events related to CTX310 in the trial and in the year following treatment.” The company adds that one participant had a transient allergic reaction and three had Grade 2 infusion-related reactions, and that no significant liver function abnormalities persisted beyond the initial treatment period.
The limits are the ones that come with a first-in-human study: only 15 participants were enrolled, the therapy remains experimental, and a gene edit cannot be withdrawn if a problem appears later. For that reason the FDA has recommended long-term safety monitoring, which the release puts at 15 years. A phase 1b program is under way, with updates expected in the second half of 2026 and a focus on patients with severe hypertriglyceridemia.
What a year of low LDL does for heart attacks and strokes is not yet known; the trial measured lipids and safety, not cardiovascular events. The figure that will decide whether CTX310 moves past 15 patients is therefore the fifteen-year safety record the FDA has asked for, not the 52.5% already on the page.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
More from Morning Overview
- The NSA is again telling phone owners to switch off one location setting
- Supplements now rank as the fifth-leading cause of death from liver disease.
- Herbal supplements are landing Americans in the hospital with liver damage, doctors warn
- General Motors is switching on cameras that record inside your vehicle by update
